SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the Nov. 22 PDUFA date, the amended upper-limb data and new commercial-launch job postings they interpret as possible signs of readiness. Approval hopes and short-squeeze speculation are prominent, while skeptics note that hiring does not confirm an FDA outcome and cite the companys prior regulatory setback and remaining efficacy questions.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline after the first quarter of 2027 has raised concerns about pricing and revenue for CorMedixs flagship product, amid a sharp selloff. Traders are split between viewing the comments as a serious commercial risk and arguing they are preliminary and at odds with CMS estimates; many also criticize managements silence, while some are buying the dip.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios accelerated FDA approval of a treatment for recurrent respiratory papillomatosis has renewed focus on competition with Precigens PAPZIMEOS, which is already approved for the same disease. Traders are divided over how much market share the new entrant could threaten, with some calling the selloff an overreaction and pointing to Precigens head start and different approval status.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention for its breakout ahead of the expected Q3 earnings report, with traders focused on BRIUMVIs growth and possible further upside. Buyout and short-squeeze chatter is prominent but speculative; some traders instead attribute the move to earnings expectations and the companys commercial momentum.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS REGAL Phase 3 leukemia trial reached its prespecified event threshold, triggering final analysis and putting the GPS survival readout in focus. Traders are sharply divided over whether GPS will show a benefit or whether control-arm outcomes and trial assumptions could undermine the bull case, amid volatile trading and speculation about short positioning.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A steep tech-led selloff has focused discussion on fears that heavy AI infrastructure spending may not produce adequate returns, alongside concerns about persistent inflation and higher interest rates. Traders are divided on whether the drop marks an oversold buying opportunity or signals further losses, with debate also citing weak tech outlooks and volatile trading.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Silvers sharp selloff, amid inflation concerns and expectations of higher interest rates, is driving attention to SLV. Traders are split between calling the decline an oversold buying opportunity and warning that selling may continue, with some blaming market manipulation without evidence.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons strong third-quarter earnings, fueled by Eylea HD sales and higher Sanofi collaboration revenue from Dupixent, drove a sharp share-price jump and breakout discussion. Traders largely welcomed the results, while some debated whether newer drugs can sustain growth; the upcoming cemdisiran decision also drew attention.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its earnings report is driving discussion, with traders citing analyst price-target cuts and worries about growth, competition, and weakness in the broader ad market. Some expect those concerns to weigh on results, while others argue the decline is disconnected from the companys profitability and see the report as a potential sentiment test.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,874.98691422 USD and is down -4.82 over the last 24 hours. It is currently trading on 12773 active market(s) with $58,826,736,014.03 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach and temporary withdrawal disruption have intensified selling in Bitcoin and other crypto assets, amid concerns about exchange security and possible contagion. Traders disagree over whether the incident undermines confidence in Bitcoin or is an exchange-specific problem, with bearish calls and panic-selling set against dip-buying and claims that Bitcoin is holding up relatively well.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Invesco S&P Ultra Dividend Revenue ETF (RDIV) Be on Your Investing Radar?

BMY Stock Drops As Lower-Dose Lung Drug Succeeds In Trial, Higher Dose Misses

Equity

Bristol Myers reported that its late-stage ALOFT-IPF trial of the oral drug admilparant met the primary endpoint at the 60 mg twice-daily dose in patients with Idiopathic Pulmonary Fibrosis. 


Target Reports Upbeat Q2 Revenue, Improves Guidance — Retail Eyes Potential For PE Multiple Re-Rating In Coming Times

Target now expects full-year net sales growth in a range around 5%, one percentage point higher than the prior guidance range.


December Jobs Data Put Focus on These Sector ETFs & Stocks

December jobs data highlight sector shifts as healthcare and restaurants add jobs, while retail lags. ETFs XLV, EATZ in focus.

Retail Shrugs-Off Ford’s Huge Earnings Miss: But Wall Street Hammers The Stock

Earnings per share came in at $0.47 compared to a Street expectation of $0.68. Net income dropped nearly 5% year-over-year (YoY) to $1.83 billion. However, revenue came in at $47.81 billion, higher than a Street estimate of $44.88 billion.


Invesco Exchange-Traded Fund Trust II - Invesco S&P Ultra Dividend Revenue ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The higher 120 mg twice-daily dose slowed the decline in lung function but did not reach statistical significance.</li><li>The company intends to complete a full review of the data and engage health authorities about next steps toward possible regulatory filings.</li><li>Separately, the company said an interim analysis of the ACTION-1 trial studying RYZ101 in patients with gastroenteropancreatic neuroendocrine tumors met its main goal.</li></ul><p><br>Bristol Myers Squibb (BMY) shares fell roughly 3% in midday trading on Monday, reversing opening gains, after the company reported mixed results from a late-stage trial in scarring lung disease — the study succeeded only at the lower dose tested while the higher dose fell short of statistical significance.</p><p>The company also announced positive results from its late-stage trial in a rare cancer.</p><h2 class="st-heading-2">Bristol Myers' Lung-Disease Results Come With A Caveat</h2><p>Bristol Myers reported that its late-stage ALOFT-IPF trial of the oral drug admilparant met the primary endpoint at the 60 mg twice-daily dose in patients with Idiopathic Pulmonary Fibrosis (IPF).</p><p>Patients receiving that dose showed a statistically significant improvement versus placebo in the absolute change in forced vital capacity—a standard measure of lung function—at 52 weeks. The higher 120 mg twice-daily dose slowed the decline in lung function but did not reach statistical significance. The company noted that both doses were generally well tolerated, with rates of discontinuation due to side effects that were low and similar to placebo.</p><p>Executives called the overall findings supportive of admilparant as a potential first-in-class approach targeting a specific biological pathway in idiopathic pulmonary fibrosis, a progressive disease that scars the lungs and leaves patients with limited effective options.</p><p>The company intends to complete a full review of the data and engage health authorities about next steps toward possible regulatory filings. Detailed results are planned for a future medical meeting. A related late-stage study in a broader form of progressive lung fibrosis is expected to report results in early 2027.</p><h2 class="st-heading-2">Cancer Therapy Shows Stronger Signal</h2><p>Separately, the company said an interim analysis of the ACTION-1 trial met its main goal.</p><p>The study tested RYZ101, an experimental radiopharmaceutical therapy developed by its RayzeBio unit, in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) whose disease had progressed after earlier lutetium-based treatment.</p><p>RYZ101 produced a statistically significant and clinically meaningful improvement in the time patients lived without their cancer worsening, compared with standard options such as certain hormonal agents or other approved drugs. Safety findings matched what was previously known about the therapy.</p><p>Company executives described the outcome as an important milestone for patients with few remaining options after prior therapy and said they plan to discuss the data with regulators. The drug already carries orphan-drug designation for this rare disease. Detailed findings are expected at a future medical conference, and the trial will continue to track overall survival.</p><h2 class="st-heading-2">How Did BMY Retail Traders React?</h2><p>On Stocktwits, retail sentiment around BMY stock stayed within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/BMY">BMY stock</a> has gained 6% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/dow-rises-200-points-nasdaq-wavers-china-chip-competition-hits-tech-stocks-oil-climbs/cZxIi1oRB8W">Dow Rises 200 Points, Nasdaq Wavers: China Chip Competition Hits Tech Stocks, Oil Climbs</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Bristol-Myers Squibb Company logo is seen displayed on a tablet. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Bristol Myers reported that its late-stage ALOFT-IPF trial of the oral drug admilparant met the primary endpoint at the 60 mg twice-daily dose in patients with Idiopathic Pulmonary Fibrosis. 

Bristol-Myers Squibb Co.

VanEck Pharmaceutical ETF

Invesco S&P Ultra Dividend Revenue ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

RDIV Invesco S&P Ultra Dividend Revenue ETF

Fundamentals

Latest RDIV News